- ►annals.org [PDF] DB Badesch, VF Tapson, MD McGoon, BH … - Annals of Internal Medicine, 2000 - Am Coll Physicians David B. Badesch, MD; Victor F. Tapson, MD; Michael D. McGoon, MD; Bruce H.
Brundage, MD; Lewis J. Rubin, MD; Fredrick M. Wigley, MD; Stuart Rich, MD; Robyn
J. Barst, MD; Pamela S. Barrett, PharmD; Kenneth M. Kral, MS; Maria M. ... Cited by 649 - Related articles - BL Direct - All 6 versions
- ►171.66.122.149 G Simonneau, RJ Barst, N Galie, R Naeije, S … - American journal of respiratory and critical care …, 2002 - 171.66.122.149 Pulmonary arterial hypertension is a life-threatening disease for which
continuous intravenous prostacyclin has proven to be effective. However, this
treatment requires a permanent central venous catheter with the associated ... Cited by 629 - Related articles - BL Direct - All 9 versions
RJ Barst, LJ Rubin, WA Long, MD McGoon, S … - New England Journal of Medicine, 1996 - content.nejm.org Hemodynamics improved at 12 weeks in the epoprostenol-treated patients. The
changes in mean pulmonary-artery pressure for the epoprostenol and control
groups were -8 percent and +3 percent, respectively (difference in mean ... Cited by 1399 - Related articles - BL Direct - All 9 versions
H Olschewski, G Simonneau, N Galie, T … - New England Journal of Medicine, 2002 - content.nejm.org Methods We compared repeated daily inhalations of 2.5 or 5.0 µg of iloprost
(six or nine times per day; median inhaled dose, 30 µg per day) with inhalation
of placebo. A total of 203 patients with selected forms of severe pulmonary ... Cited by 845 - Related articles - BL Direct - All 19 versions
- ►ahajournals.org VV McLaughlin, A Shillington, S Rich - Circulation, 2002 - Am Heart Assoc Methods and Results— One hundred sixty-two consecutive patients diagnosed with
PPH and treated with epoprostenol were followed for a mean of 36.3 months
(median, 31 months). Data including functional class, exercise tolerance, ... Cited by 549 - Related articles - BL Direct - All 7 versions
- ►nejm.org LJ Rubin, DB Badesch, RJ Barst, N Galie, CM … - The New England journal of medicine, 2002 - nejm.highwire.org Methods In this double-blind, placebo-controlled study, we randomly assigned 213
patients with pulmonary arterial hypertension (primary or associated with
connective-tissue disease) to receive placebo or to receive 62.5 mg of ... Cited by 1390 - Related articles - BL Direct - All 17 versions
- ►ucsd.edu [PDF] RN Channick, G Simonneau, O Sitbon, IM … - The Lancet, 2001 - Elsevier In patients given bosentan, the distance walked in 6 min improved by 70 m at 12
weeks compared with baseline, whereas it worsened by 6 m in those on placebo
(difference 76 m [95% CI 12-139], p=0<021). The improvement was maintained ... Cited by 838 - Related articles - BL Direct - All 11 versions
- ►utmem.edu [PDF] MM Hoeper, M Schwarze, S Ehlerding, A … - New England Journal of Medicine, 2000 - content.nejm.org Results Twenty-four patients with primary pulmonary hypertension received
aerosolized iloprost at a daily dose of 100 or 150 µg for at least one year.
The mean (±SD) distance covered in the six-minute walk test increased from ... Cited by 457 - Related articles - BL Direct - All 11 versions
- ►onlinejacc.org O Sitbon, M Humbert, H Nunes, F Parent, G … - Journal of the American College of Cardiology, 2002 - Elsevier Epoprostenol improves survival in patients with PPH in New York Heart
Association (NYHA) functional class III or IV. However, some patients do not
benefit from epoprostenol and must be considered for lung transplantation. ... Cited by 592 - Related articles - BL Direct - All 11 versions
- ►onlinejacc.org N Galie, M Humbert, JL Vachiery, CD Vizza, M … - Journal of the American College of Cardiology, 2002 - Elsevier Patients treated with beraprost improved exercise capacity and symptoms. The
difference between treatment groups in the mean change of 6-min walking distance
at week 12 was 25.1 m (95% confidence interval [CI]: 1.8 to 48.3, P = ... Cited by 342 - Related articles - BL Direct - All 13 versions
